Aeglea BioTherapeutics Announces Upcoming KOL and Patient Caregiver Webinar on Arginase 1 Deficiency
01/25/2022 - 08:01 AM
AUSTIN, Texas , Jan. 25, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit people with rare metabolic diseases, today announced that it will host a Key Opinion Leader (KOL) and Patient Caregiver Webinar on Arginase 1 Deficiency on Thursday, February 3, 2022 , at 2:30pm EST .
The webinar will include presentations from:
Barbara Burton , M.D., Professor of Pediatrics, Northwestern University Feinberg School of Medicine, and Attending Physician in the Division of Genetics, Birth Defects and Metabolism at the Ann & Robert H. Lurie Children's Hospital of Chicago, will provide an overview of Arginase 1 Deficiency and describe the role of arginine in the pathogenesis of the disease. George Diaz , M.D., Ph.D., Professor of Genetics and Genomic Sciences, Icahn School of Medicine, and Director of the Program for Inherited Metabolic Diseases at Mount Sinai (New York, NY ), will discuss the enzyme therapy approach to treating patients with Arginase 1 Deficiency and clinical data. Tanja Brandt , parent/caregiver of a 10-year-old child with Arginase 1 Deficiency, Advisor and Steering Committee Member of the Arginase 1 Deficiency Foundation (ARG1D.org), will discuss the disease burden and will provide the patient and caregiver perspective related to the challenges of living with a devastating and progressive disease. A live question and answer session will follow the formal presentations. To register for the webinar, please click here . To access the live and/or archived webcast, visit the Events & Presentations section of the Company' s website. Replays of Company webcasts are archived on the website for 30 days following presentations.
About Aeglea BioTherapeutics
Aeglea BioTherapeutics is a clinical-stage biotechnology company redefining the potential of human enzyme therapeutics to benefit people with rare metabolic diseases with limited treatment options. In December 2021 , Aeglea announced positive topline data from its PEACE Phase 3 clinical trial for its lead product candidate, pegzilarginase, in patients with Arginase 1 Deficiency. Pegzilarginase has received both Rare Pediatric Disease and Breakthrough Therapy designations. Aeglea also has an ongoing Phase 1/2 clinical trial of AGLE-177 for the treatment of Homocystinuria. AGLE-177 has been granted Rare Pediatric Disease Designation. Aeglea has an active discovery platform focused on engineering small changes in human enzymes to have a big impact on the lives of patients and their families. For more information, please visit http://aeglea.com .
https://www.prnewswire.com/news-releases/aeglea-biotherapeutics-announces-upcoming-kol-and-patient-caregiver-webinar-on-arginase-1-deficiency-301466577.html
SOURCE Aeglea BioTherapeutics, Inc.
Aeglea BioTherapeutics Inc
AGLE Rankings
#4882 Ranked by Stock Gains
AGLE Stock Data
Industry
Pharmaceutical Preparation Manufacturing
Sector
Manufacturing
Tags
Health Technology, Pharmaceuticals: Major, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
About AGLE
aeglea was founded in december of 2013 to develop engineered human enzymes invented in the laboratory of george georgiou, ph.d. of the university of texas at austin. the convergence of discovery and technology has created a significant opportunity for aeglea to impact both the treatment of inborn errors of metabolism and cancer. three drug candidates that degrade specific amino acids in the circulation are in development. for inborn errors of metabolism efforts are underway to normalize high arginine levels in patients who suffer from a gene mutation in the arginine degrading enzyme arginase1 and for patients who have mutations leading to excess levels of homocysteine. taking advantage of a cancer’s metabolic vulnerability and selectively killing only the tumor through deprivation of arginine, cysteine/cystine, and methionine are techniques in development for multiple oncology indications. coupling amino acid depletion therapy with the development of diagnostics for each oncology f
